AU2019236105B2 - Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis - Google Patents

Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis

Info

Publication number
AU2019236105B2
AU2019236105B2 AU2019236105A AU2019236105A AU2019236105B2 AU 2019236105 B2 AU2019236105 B2 AU 2019236105B2 AU 2019236105 A AU2019236105 A AU 2019236105A AU 2019236105 A AU2019236105 A AU 2019236105A AU 2019236105 B2 AU2019236105 B2 AU 2019236105B2
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
acid sequence
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019236105A
Other languages
English (en)
Other versions
AU2019236105A1 (en
Inventor
Janine LAMAR
Steven John PADULA
Christian Thoma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of AU2019236105A1 publication Critical patent/AU2019236105A1/en
Application granted granted Critical
Publication of AU2019236105B2 publication Critical patent/AU2019236105B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2019236105A 2018-03-14 2019-03-08 Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis Active AU2019236105B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862642641P 2018-03-14 2018-03-14
US62/642,641 2018-03-14
US201862683720P 2018-06-12 2018-06-12
US62/683,720 2018-06-12
US201862699274P 2018-07-17 2018-07-17
US62/699,274 2018-07-17
US201862729518P 2018-09-11 2018-09-11
US62/729,518 2018-09-11
PCT/US2019/021335 WO2019177888A1 (en) 2018-03-14 2019-03-08 Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis

Publications (2)

Publication Number Publication Date
AU2019236105A1 AU2019236105A1 (en) 2020-08-27
AU2019236105B2 true AU2019236105B2 (en) 2025-07-31

Family

ID=65904556

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019236105A Active AU2019236105B2 (en) 2018-03-14 2019-03-08 Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis

Country Status (13)

Country Link
US (2) US20190284285A1 (https=)
EP (1) EP3765513A1 (https=)
JP (2) JP7404256B2 (https=)
KR (1) KR102768040B1 (https=)
CN (1) CN112272674A (https=)
AU (1) AU2019236105B2 (https=)
BR (1) BR112020016738A2 (https=)
CA (1) CA3093692A1 (https=)
CL (1) CL2020002342A1 (https=)
IL (1) IL277215B2 (https=)
MX (1) MX2020009544A (https=)
PH (1) PH12020551444A1 (https=)
WO (1) WO2019177888A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925932A (zh) 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
BR112020016738A2 (pt) 2018-03-14 2020-12-15 Boehringer Ingelheim International Gmbh Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada
AU2019306217B2 (en) 2018-07-16 2024-01-25 Regeneron Pharmaceuticals, Inc. Anti-IL36R antibodies
TW202037604A (zh) * 2018-12-27 2020-10-16 德商百靈佳殷格翰國際股份有限公司 治療掌蹠膿疱症之抗il-36r抗體
IL286100B2 (en) 2019-03-08 2024-12-01 Boehringer Ingelheim Int Anti-il-36r antibody formulations
BR112022026999A2 (pt) * 2020-07-17 2023-01-24 Boehringer Ingelheim Int Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
EP4188441A1 (en) * 2020-07-30 2023-06-07 AnaptysBio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
WO2022026829A1 (en) * 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
CN121324513A (zh) * 2020-09-16 2026-01-13 上海市皮肤病医院 基于代谢组学的泛发性脓疱型银屑病诊断标志物及其应用
EP4221839A1 (en) * 2020-09-30 2023-08-09 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for treatment of chronic inflammatory pain
CN114907477A (zh) * 2021-02-08 2022-08-16 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
CA3209006A1 (en) * 2021-03-04 2022-09-09 Boehringer Ingelheim International Gmbh Methods for the treatment of gpp
EP4305207A2 (en) * 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
JP2024518536A (ja) * 2021-05-12 2024-05-01 アナプティスバイオ インコーポレイティッド 抗体組成物
CN113274494B (zh) * 2021-06-07 2022-09-20 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的重组全人源单克隆抗体的液体制剂
CN115327130A (zh) * 2022-07-25 2022-11-11 深圳市妇幼保健院 一种免疫生物标志物在制备小儿脓毒血症诊断试剂盒中的应用
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013074569A1 (en) * 2011-11-16 2013-05-23 Boehringer Ingelheim International Gmbh Anti il-36r antibodies
WO2016168542A1 (en) * 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CA2635352C (en) 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
EP1003861B1 (en) 1997-08-01 2006-10-04 Schering Corporation Mammalian cell membrane proteins; related reagents
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
DE19733389C2 (de) 1997-08-01 1999-08-19 Deutsches Krebsforsch Mittel zur Expression und zum Nachweis eines ein HPOL-Epitop und ein Polypeptid enthaltenden Fusionspolypeptids
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
EP1627927A3 (en) 2001-03-01 2006-06-07 Epigenomics AG Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
AU2003282667A1 (en) 2002-10-03 2004-04-23 Large Scale Biology Corporation Multimeric protein engineering
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101389769A (zh) 2005-12-28 2009-03-18 森托科尔公司 用于评价和治疗银屑病及相关疾病的标记与方法
WO2008033333A2 (en) 2006-09-08 2008-03-20 Amgen Inc. Il-1 family variants
WO2008133857A1 (en) 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies
ES2540854T3 (es) 2007-06-29 2015-07-14 Merck Sharp & Dohme Corp. Usos de antagonistas MDL-1
WO2009040602A1 (en) 2007-09-25 2009-04-02 Becton Dickinson France Autoinject0r with deactivating means moveable by a safety shield
CA2701717C (en) 2007-10-06 2016-11-29 Arbitron, Inc. Gathering research data
KR20110048536A (ko) 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
EP2458990B1 (en) 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
LT2805731T (lt) 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
EP2575884B1 (en) 2010-06-03 2018-07-18 AbbVie Biotechnology Ltd Uses and compositions for treatment of hidradenitis suppurativa (hs)
KR102063028B1 (ko) 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ａｎｇ2 항체를 함유하는 안정화된 제형
CH705992A2 (de) 2012-10-11 2013-06-14 Tecpharma Licensing Ag Injektionsvorrichtung.
WO2015022656A1 (en) 2013-08-15 2015-02-19 Novartis Ag Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
EP3194583B1 (en) 2014-07-30 2021-09-15 Zumutor Biologics, Inc. Non-fucosylated protein and methods thereof
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN112870489B (zh) 2015-04-24 2022-12-06 艾斯曲尔医疗公司 药剂输送装置的子组件和药剂输送装置
CH711066A2 (de) 2015-05-13 2016-11-15 Tecpharma Licensing Ag Verbesserte Injektionsvorrichtung.
CN106470162B (zh) 2015-08-19 2019-06-25 中国移动通信集团公司 一种业务报文的组播方法及装置
JP6654773B2 (ja) 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
CN115400220A (zh) 2015-12-30 2022-11-29 豪夫迈·罗氏有限公司 减少聚山梨酯降解的制剂
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
CN107362351B (zh) 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
JP2021517577A (ja) 2018-03-14 2021-07-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性腸疾患の処置のための抗ｉｌ−３６ｒ抗体の使用
BR112020016738A2 (pt) 2018-03-14 2020-12-15 Boehringer Ingelheim International Gmbh Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada
AU2019306217B2 (en) 2018-07-16 2024-01-25 Regeneron Pharmaceuticals, Inc. Anti-IL36R antibodies
HRP20240999T1 (hr) 2018-07-16 2024-10-25 Regeneron Pharmaceuticals, Inc. Glodavački modeli bolesti ditra i njihova upotreba
TW202037604A (zh) 2018-12-27 2020-10-16 德商百靈佳殷格翰國際股份有限公司 治療掌蹠膿疱症之抗il-36r抗體
IL286100B2 (en) 2019-03-08 2024-12-01 Boehringer Ingelheim Int Anti-il-36r antibody formulations
KR102708558B1 (ko) 2019-06-20 2024-09-24 삼성전자주식회사 수직형 메모리 장치
CN115427439A (zh) 2019-10-30 2022-12-02 德克萨斯A&M大学系统 用于双靶标嵌合抗原受体t细胞疗法的蛋白酶开关
BR112022026999A2 (pt) 2020-07-17 2023-01-24 Boehringer Ingelheim Int Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
EP4221839A1 (en) 2020-09-30 2023-08-09 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for treatment of chronic inflammatory pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013074569A1 (en) * 2011-11-16 2013-05-23 Boehringer Ingelheim International Gmbh Anti il-36r antibodies
US20130236471A1 (en) * 2011-11-16 2013-09-12 Boehringer Ingelheim Gmbh Anti il-36r antibodies
WO2016168542A1 (en) * 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)

Also Published As

Publication number Publication date
IL277215B1 (en) 2025-06-01
JP2024028951A (ja) 2024-03-05
CA3093692A1 (en) 2019-09-19
AU2019236105A1 (en) 2020-08-27
JP7404256B2 (ja) 2023-12-25
MX2020009544A (es) 2020-10-05
KR20200131871A (ko) 2020-11-24
CN112272674A (zh) 2021-01-26
IL277215A (en) 2020-10-29
EP3765513A1 (en) 2021-01-20
WO2019177888A1 (en) 2019-09-19
JP2021517566A (ja) 2021-07-26
PH12020551444A1 (en) 2021-08-23
JP7673168B2 (ja) 2025-05-08
CL2020002342A1 (es) 2020-12-18
IL277215B2 (en) 2025-10-01
US12503512B2 (en) 2025-12-23
US20190284285A1 (en) 2019-09-19
US20210087285A1 (en) 2021-03-25
KR102768040B1 (ko) 2025-02-17
BR112020016738A2 (pt) 2020-12-15

Similar Documents

Publication Publication Date Title
AU2019236105B2 (en) Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
US20230131364A1 (en) Anti-il-36r antibodies for treatment of palmoplantar pustulosis
KR101841527B1 (ko) 개선된 고농도 항－ＴＮＦα 항체 액체 제형
US20240352137A1 (en) Methods for the treatment of gpp
US20220010022A1 (en) Anti-il-36r antibodies for the treatment of atopic dermatitis
TW202317184A (zh) 用於治療異位性皮膚炎和相關障礙之方法
EA046186B1 (ru) Применение антител к il-36r для лечения генерализованного пустулёзного псориаза
EA049580B1 (ru) Способы лечения гпп
CN116963776A (zh) 治疗gpp的方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)